TMArQ cell count scoring was validated versus e.g., pathological estimates, gene expression data, TP53 mutational status, and patient outcome in three TMA tumour cohorts, but also compared to output from a commonly used digital image analysis software (QuPath). Here, TP53 is linked to neoplasm.